Valeritas Holdings Inc (NASDAQ:VLRX) was the recipient of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 3,745,529 shares, a growth of 43.4% from the February 15th total of 2,612,523 shares. Currently, 4.9% of the shares of the stock are sold short. Based on an average trading volume of 3,088,515 shares, the short-interest ratio is currently 1.2 days.

Shares of NASDAQ:VLRX opened at $0.39 on Friday. The company has a debt-to-equity ratio of 2.82, a current ratio of 4.47 and a quick ratio of 3.98. The firm has a market capitalization of $9.98 million, a price-to-earnings ratio of -0.23 and a beta of 2.10. Valeritas has a 52-week low of $0.30 and a 52-week high of $4.58.

In other news, major shareholder Armistice Capital Master Fund purchased 150,000 shares of the stock in a transaction dated Thursday, December 20th. The shares were purchased at an average cost of $0.34 per share, with a total value of $51,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.80% of the company’s stock.

Large investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its position in shares of Valeritas by 138.0% during the 4th quarter. Geode Capital Management LLC now owns 186,971 shares of the company’s stock valued at $60,000 after acquiring an additional 108,416 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Valeritas during the 4th quarter valued at about $165,000. Weiss Multi Strategy Advisers LLC acquired a new position in shares of Valeritas during the 4th quarter valued at about $41,000. CVI Holdings LLC acquired a new position in shares of Valeritas during the 4th quarter valued at about $832,000. Finally, Northern Trust Corp boosted its position in shares of Valeritas by 855.4% during the 4th quarter. Northern Trust Corp now owns 185,469 shares of the company’s stock valued at $60,000 after acquiring an additional 166,057 shares during the last quarter.

Several brokerages have issued reports on VLRX. Zacks Investment Research cut shares of Valeritas from a “buy” rating to a “hold” rating in a research note on Saturday, March 9th. Oppenheimer restated a “buy” rating on shares of Valeritas in a research report on Monday, January 14th. Finally, BTIG Research initiated coverage on shares of Valeritas in a research report on Tuesday, December 4th. They set a “buy” rating and a $1.00 price target on the stock. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $2.10.

TRADEMARK VIOLATION WARNING: This report was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2019/03/16/valeritas-holdings-inc-vlrx-sees-significant-increase-in-short-interest.html.

Valeritas Company Profile

Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.

Featured Story: Options Trading

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.